215 related articles for article (PubMed ID: 35731974)
1. Preclinical platforms to study therapeutic efficacy of human γδ T cells.
Ou L; Wang H; Huang H; Zhou Z; Lin Q; Guo Y; Mitchell T; Huang AC; Karakousis G; Schuchter L; Amaravadi R; Guo W; Salvino J; Herlyn M; Xu X
Clin Transl Med; 2022 Jun; 12(6):e814. PubMed ID: 35731974
[TBL] [Abstract][Full Text] [Related]
2. Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.
Wang H; Chen H; Liu S; Zhang J; Lu H; Somasundaram R; Choi R; Zhang G; Ou L; Scholler J; Tian S; Dong L; Yeye G; Huang L; Connelly T; Li L; Huang A; Mitchell TC; Fan Y; June CH; Mills GB; Guo W; Herlyn M; Xu X
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34937742
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
[TBL] [Abstract][Full Text] [Related]
4. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
5. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Exhausted intratumoral Vδ2
Rancan C; Arias-Badia M; Dogra P; Chen B; Aran D; Yang H; Luong D; Ilano A; Li J; Chang H; Kwek SS; Zhang L; Lanier LL; Meng MV; Farber DL; Fong L
Nat Immunol; 2023 Apr; 24(4):612-624. PubMed ID: 36928415
[TBL] [Abstract][Full Text] [Related]
8. Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.
Tomogane M; Sano Y; Shimizu D; Shimizu T; Miyashita M; Toda Y; Hosogi S; Tanaka Y; Kimura S; Ashihara E
Biochem Biophys Res Commun; 2021 Oct; 573():132-139. PubMed ID: 34407491
[TBL] [Abstract][Full Text] [Related]
9. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
10. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
[TBL] [Abstract][Full Text] [Related]
11. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating γδ T cells as targets of immune checkpoint blockade in melanoma.
Di Simone M; Corsale AM; Toia F; Shekarkar Azgomi M; Di Stefano AB; Lo Presti E; Cordova A; Montesano L; Dieli F; Meraviglia S
J Leukoc Biol; 2024 Mar; 115(4):760-770. PubMed ID: 38324004
[TBL] [Abstract][Full Text] [Related]
13. Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.
Cordova A; Toia F; La Mendola C; Orlando V; Meraviglia S; Rinaldi G; Todaro M; Cicero G; Zichichi L; Donni PL; Caccamo N; Stassi G; Dieli F; Moschella F
PLoS One; 2012; 7(11):e49878. PubMed ID: 23189169
[TBL] [Abstract][Full Text] [Related]
14. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract][Full Text] [Related]
15. γδ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways.
Jiang H; Yang Z; Song Z; Green M; Song H; Shao Q
Int Immunopharmacol; 2019 May; 70():167-173. PubMed ID: 30802679
[TBL] [Abstract][Full Text] [Related]
16. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
de Vries NL; van de Haar J; Veninga V; Chalabi M; Ijsselsteijn ME; van der Ploeg M; van den Bulk J; Ruano D; van den Berg JG; Haanen JB; Zeverijn LJ; Geurts BS; de Wit GF; Battaglia TW; Gelderblom H; Verheul HMW; Schumacher TN; Wessels LFA; Koning F; de Miranda NFCC; Voest EE
Nature; 2023 Jan; 613(7945):743-750. PubMed ID: 36631610
[TBL] [Abstract][Full Text] [Related]
17. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
18. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
19. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
20. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
